Jade Biosciences Inc. AVTE
$15.26
▲ +0.26% 24H
About
Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees55
TickerAVTE
Statistics
Market Cap$442.3M
Revenue (TTM)$0
Net Income-$69.6M
Net Margin—
EPS—
P/E—
P/S—
P/B—
EV/EBITDA-5.50
ROE-91.1%
Dividend Yield—
Price$15.26
Data: Twelve Data · Revenue = mcap / P/S